Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
1.
J Environ Manage ; 359: 121077, 2024 May.
Artículo en Inglés | MEDLINE | ID: mdl-38718604

RESUMEN

Tetrabromobisphenol A (TBBPA) and microplastics are emerging contaminants of widespread concern. However, little is known about the effects of combined exposure to TBBPA and microplastics on the physicochemical properties and microbial metabolism of anaerobic granular sludge. This study investigated the effects of TBBPA, polystyrene microplastics (PS MP) and polybutylene succinate microplastics (PBS MP) on the physicochemical properties, microbial communities and microbial metabolic levels of anaerobic granular sludge. The results showed that chemical oxygen demand (COD) removal of sludge was lowest in the presence of TBBPA alone and PS MP alone with 33.21% and 30.06%, respectively. The microorganisms promoted the secretion of humic substances under the influence of TBBPA, PS MP and PBS MP. The lowest proportion of genes controlling glycolytic metabolism in sludge was 1.52% when both TBBPA and PS MP were added. Microbial reactive oxygen species were increased in anaerobic granular sludge exposed to MPS. In addition, TBBPA treatment decreased electron transfer of the anaerobic granular sludge and disrupted the pathway of anaerobic microorganisms in acquiring adenosine triphosphate, and MPs attenuated the negative effects of TBBPA on the acetate methanogenesis process of the anaerobic granular sludge. This study provides a reference for evaluating the impact of multiple pollutants on anaerobic granular sludge.


Asunto(s)
Microplásticos , Bifenilos Polibrominados , Aguas del Alcantarillado , Bifenilos Polibrominados/toxicidad , Bifenilos Polibrominados/metabolismo , Microplásticos/toxicidad , Anaerobiosis , Especies Reactivas de Oxígeno/metabolismo
2.
Anal Bioanal Chem ; 412(19): 4549-4554, 2020 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-32533226

RESUMEN

Anti-PLA2R antibody is only expressed in podocytes from patients with idiopathic membranous nephropathy (IMN). The detection of anti-PLA2R antibody in serum is therefore able to obtain essential information for rapid diagnosis and evaluation of the disease activity of IMN. In the present study, a polydopamine nanosphere-based fluorescent sensor was constructed for direct detection of anti-PLA2R antibodies in human serum. In this sensing system, the double-stranded DNA was phosphorylated under the action of anti-PLA2R antibody and the single-stranded DNA was cut by exonuclease. The single-stranded DNA was then adsorbed on polydopamine microspheres. The fluorescent groups labeled on the DNA were quenched, and the concentration of anti-PLA2R antibody was detected quantitatively by measuring the fluorescence signal changes before and after the reaction. The experimental results show that the method has a good linear detection range between 0.05 and 10 µg/mL for anti-PLA2R antibody and the detection limit is 0.02 µg/mL. Graphical abstract.


Asunto(s)
Anticuerpos/sangre , Técnicas Biosensibles/métodos , Glomerulonefritis Membranosa/sangre , Indoles/química , Nanosferas/química , Polímeros/química , Receptores de Fosfolipasa A2/inmunología , Anticuerpos/inmunología , Biomarcadores/sangre , Glomerulonefritis Membranosa/diagnóstico , Glomerulonefritis Membranosa/inmunología , Humanos , Ácidos Nucleicos Inmovilizados/química , Límite de Detección , Espectrometría de Fluorescencia/métodos
3.
Nanomedicine ; 14(6): 1949-1961, 2018 08.
Artículo en Inglés | MEDLINE | ID: mdl-29045824

RESUMEN

HAb18G/CD147, an important marker in the progression of hepatocellular carcinoma (HCC), is highly expressed on the surface of HCC cells. To increase the therapeutic efficacy of Doxil (PEGylated liposomal doxorubicin) against HCC, we constructed CD147-targeted doxorubicin-loaded immunoliposomes (Anti-CD147 ILs-DOX) by conjugating F(ab')2 of a CD147-specific monoclonal antibody to DSPE-PEG-MAL, and then inserted the antibody-conjugated polymer to Doxil. Anti-CD147 ILs-DOX delivered DOX to CD147-overexpressing HCC cells specifically and efficiently in vitro and in vivo, resulting in enhanced therapeutic effects than non-targeted controls. Strikingly, Anti-CD147 ILs-DOX reduced the CD133-positive fraction of HCC cells, suggesting its potential in reducing the number of HCC stem cells. Pharmacokinetic and biodistribution studies of Anti-CD147 ILs-DOX confirmed its long circulation time and efficient accumulation in tumors. The superior antitumor effects of Anti-CD147 ILs-DOX than other treatments were demonstrated in both HCC cells and patient-derived HCC xenograft models. Anti-CD147 ILs-DOX represent a novel approach for targeted HCC therapy.


Asunto(s)
Anticuerpos Monoclonales/química , Basigina/inmunología , Carcinoma Hepatocelular/tratamiento farmacológico , Doxorrubicina/análogos & derivados , Sistemas de Liberación de Medicamentos , Inmunoconjugados/administración & dosificación , Neoplasias Hepáticas/tratamiento farmacológico , Animales , Antibióticos Antineoplásicos/administración & dosificación , Antibióticos Antineoplásicos/farmacocinética , Anticuerpos Monoclonales/inmunología , Apoptosis/efectos de los fármacos , Carcinoma Hepatocelular/inmunología , Carcinoma Hepatocelular/patología , Proliferación Celular/efectos de los fármacos , Doxorrubicina/administración & dosificación , Doxorrubicina/farmacocinética , Femenino , Humanos , Neoplasias Hepáticas/inmunología , Neoplasias Hepáticas/patología , Ratones , Ratones Endogámicos BALB C , Ratones Desnudos , Polietilenglicoles/administración & dosificación , Polietilenglicoles/farmacocinética , Distribución Tisular , Células Tumorales Cultivadas , Ensayos Antitumor por Modelo de Xenoinjerto
4.
Chem Biol Interact ; 395: 111015, 2024 May 25.
Artículo en Inglés | MEDLINE | ID: mdl-38663797

RESUMEN

Hepatic fibrosis is a complex chronic liver disease in which both macrophages and hepatic stellate cells (HSCs) play important roles. Many studies have shown that clodronate liposomes (CLD-lipos) effectively deplete macrophages. However, no liposomes have been developed that target both HSCs and macrophages. This study aimed to evaluate the therapeutic efficacy of lipopolysaccharide-coupled clodronate liposomes (LPS-CLD-lipos) and the effects of liposomes size on hepatic fibrosis. Three rat models of hepatic fibrosis were established in vivo; diethylnitrosamine (DEN), bile duct ligation (BDL), and carbon tetrachloride (CCl4). Hematoxylin and eosin staining and serological liver function indices were used to analyze pathological liver damage. Masson's trichrome and Sirius red staining were used to evaluate the effect of liposomes on liver collagen fibers. The hydroxyproline content in liver tissues was determined. In vitro cell counting kit-8 (CCK-8) and immunofluorescence assays were used to further explore the effects of LPS modification and liposomes size on the killing of macrophages and HSCs. Both in vitro and in vivo experiments showed that 200 nm LPS-CLD-lipos significantly inhibited hepatic fibrosis and the abnormal deposition of collagen fibers in the liver and improved the related indicators of liver function. Further results showed that 200 nm LPS-CLD-lipos increased the clearance of macrophages and induced apoptosis of hepatic stellate cells, significantly. The present study demonstrated that 200 nm LPS-CLD-lipos could significantly inhibit hepatic fibrosis and improve liver function-related indices and this study may provide novel ideas and directions for hepatic fibrosis treatment.


Asunto(s)
Ácido Clodrónico , Células Estrelladas Hepáticas , Lipopolisacáridos , Liposomas , Cirrosis Hepática , Macrófagos , Ratas Sprague-Dawley , Animales , Células Estrelladas Hepáticas/efectos de los fármacos , Células Estrelladas Hepáticas/metabolismo , Liposomas/química , Lipopolisacáridos/farmacología , Ácido Clodrónico/farmacología , Ácido Clodrónico/química , Ácido Clodrónico/uso terapéutico , Cirrosis Hepática/tratamiento farmacológico , Cirrosis Hepática/patología , Cirrosis Hepática/metabolismo , Cirrosis Hepática/inducido químicamente , Ratas , Macrófagos/efectos de los fármacos , Macrófagos/metabolismo , Masculino , Hígado/efectos de los fármacos , Hígado/patología , Hígado/metabolismo , Células RAW 264.7 , Ratones , Tetracloruro de Carbono/toxicidad
5.
Int J Pharm ; 629: 122346, 2022 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-36334635

RESUMEN

Macrophages in the liver have capacities of capturing and phagocytosing nanocarriers. Macrophages also play an important role in the inflammatory microenvironment and in the tumorigenesis, development and progression of hepatocellular carcinoma (HCC). Several studies have shown that depletion of macrophages is a viable strategy for drug delivery and tumor microenvironment regulation. We prepared liposomes containing doxorubicin and clodronate using an ammonium sulfate gradient and thin film hydration method. The repressive therapeutic effects of liposomes were compared by intrasplenic injection at different stages of a primary HCC model induced by diethylnitrosamine (DEN) in rats. Doxorubicin-liposome (DOX-LIP) and clodronate-liposome (CL-LIP) about 180-200 nm were successfully prepared and characterized. We found that DOX-LIP combined with CL-LIP could effectively inhibit the occurrence and development of liver cancer without major organ damage and side effects. The combination of doxorubicin and clodronate liposomes notably decreased hepatic CD68 + macrophages, enriched DOX in plasma and accumulated it for a long time in the liver and spleen, thus improving the tumor microenvironment, inhibiting the activation of hepatic progenitor cells (HPCs) and promoting the apoptosis of tumor cells, and finally producing the inhibitory and therapeutic effects of HCC in rats. Results of this study were expected to provide a new prospect for the chemotherapy of HCC.


Asunto(s)
Carcinoma Hepatocelular , Neoplasias Hepáticas , Ratas , Animales , Liposomas , Carcinoma Hepatocelular/tratamiento farmacológico , Carcinoma Hepatocelular/patología , Ácido Clodrónico/farmacología , Ácido Clodrónico/uso terapéutico , Neoplasias Hepáticas/tratamiento farmacológico , Neoplasias Hepáticas/patología , Doxorrubicina , Macrófagos/patología , Línea Celular Tumoral , Microambiente Tumoral
6.
Sci Rep ; 6: 20896, 2016 Feb 11.
Artículo en Inglés | MEDLINE | ID: mdl-26864651

RESUMEN

Hepatic metastasis is the leading cause of mortality of colon cancer, which is still lack of an effective therapy. A new delivery system, pluronic P85 block copolymers, conveying chemotherapeutic agent 5-fluorouracil (5-Fu) for inhibiting growth and metastasis of colon cancer was designed and developed. In this study, we demonstrated that 5-Fu produce strong pesticide effect at lower doses in the present of pluronic P85 compared with control groups. The migration and invasion of HCT116 cells and RKO cells were examined and the results showed that migration and invasion capacities of HCT116 cells and RKO cells were reduced by administering 5-Fu/P85 copolymer micelles in vitro and in vivo which indicating an effectively activity. Interestingly, the content of CD133 + CXCR4+ cells in HCT116 cancer cells and RKO cells treated by 5-Fu/P85 copolymer micelles was decreased. Importantly, the epithelial-mesenchymal transition (EMT) of CD133 + CXCR4+ cells, which was strongly associated with liver metastasis of colon cancer, was also suppressed by giving 5-Fu/P85 copolymer micelles. The results indicated that 5-Fu/P85 copolymer micelles could inhibit the growth and metastasis of colon cancer, which could be attributed to the decrease of the content of CD133 + CXCR4+ cells and suppression of EMT of CD133 + CXCR4+ cells.


Asunto(s)
Antineoplásicos/farmacología , Neoplasias del Colon/tratamiento farmacológico , Portadores de Fármacos , Fluorouracilo/farmacología , Neoplasias Hepáticas/tratamiento farmacológico , Poloxaleno/química , Antígeno AC133/genética , Antígeno AC133/metabolismo , Animales , Antineoplásicos/química , Línea Celular Tumoral , Movimiento Celular/efectos de los fármacos , Neoplasias del Colon/genética , Neoplasias del Colon/mortalidad , Neoplasias del Colon/patología , Composición de Medicamentos , Liberación de Fármacos , Fluorouracilo/química , Expresión Génica , Células HCT116 , Humanos , Inyecciones Intravenosas , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/mortalidad , Neoplasias Hepáticas/secundario , Masculino , Ratones , Ratones Desnudos , Micelas , Invasividad Neoplásica , Receptores CXCR4/genética , Receptores CXCR4/metabolismo , Vena Esplénica , Análisis de Supervivencia , Ensayos Antitumor por Modelo de Xenoinjerto
7.
Chem Biol Drug Des ; 86(4): 783-94, 2015 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-25739815

RESUMEN

Although chemotherapy plays a vital role in treating non-Hodgkin lymphomas, the clinical applications are limited because of intolerable side-effects and multidrug resistance at the beginning or during the course of therapy. In this study, we successfully fabricated a CD20-targeting immuno-liposome based on 1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine (DC-8,9PC), which can form intermolecular cross-linking through the diacetylenic group by ultraviolet irradiation. This immuno-liposome showed appropriate size distribution, well-defined regular spherical structure, favorable biocompatibility, high serum stability, and prolonged circulation time in blood vessels. The in and ex vivo experiments demonstrate enhanced tumor suppression abilities against both wild-type and resistant non-Hodgkin lymphomas for liposomal doxorubicin when compared with free drugs. The outstanding antitumor activities are attributed to the accumulation and retention of liposomal drugs in malignant tissues and cells, which are realized by the co-operation of active targeting via antibody-antigen reaction and passive targeting via enhanced permeability and retention effect.


Asunto(s)
Antibióticos Antineoplásicos/administración & dosificación , Preparaciones de Acción Retardada/química , Diinos/química , Doxorrubicina/análogos & derivados , Sistemas de Liberación de Medicamentos , Liposomas/química , Linfoma no Hodgkin/tratamiento farmacológico , Fosfatidilcolinas/química , Animales , Antibióticos Antineoplásicos/farmacología , Antibióticos Antineoplásicos/uso terapéutico , Anticuerpos Inmovilizados/química , Anticuerpos Inmovilizados/inmunología , Antígenos CD20/inmunología , Línea Celular Tumoral , Doxorrubicina/administración & dosificación , Doxorrubicina/farmacocinética , Doxorrubicina/uso terapéutico , Femenino , Humanos , Fragmentos Fab de Inmunoglobulinas/química , Fragmentos Fab de Inmunoglobulinas/inmunología , Liposomas/inmunología , Linfoma no Hodgkin/inmunología , Ratones SCID , Polietilenglicoles/administración & dosificación , Polietilenglicoles/farmacocinética , Polietilenglicoles/uso terapéutico , Rituximab/química , Rituximab/inmunología , Rayos Ultravioleta
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA